Stem definition | Drug id | CAS RN |
---|---|---|
928 | 97-77-8 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 24.09 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 28, 1951 | FDA |
None
None
Source | Code | Description |
---|---|---|
ATC | N07BB01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in alcohol dependence |
ATC | P03AA04 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES Sulfur containing products |
ATC | P03AA54 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS ECTOPARASITICIDES, INCL. SCABICIDES Sulfur containing products |
MeSH PA | D065086 | Acetaldehyde Dehydrogenase Inhibitors |
FDA MoA | N0000000183 | Acetyl Aldehyde Dehydrogenase Inhibitors |
FDA EPC | N0000175679 | Aldehyde Dehydrogenase Inhibitor |
MeSH PA | D000427 | Alcohol Deterrents |
CHEBI has role | CHEBI:48422 | angiogenesis inhibitor |
CHEBI has role | CHEBI:24127 | fungicide |
CHEBI has role | CHEBI:35610 | antineoplastic agent |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Alcoholism | indication | 7200002 | |
Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
Chronic glomerulonephritis | contraindication | 20917003 | |
Alcohol intoxication | contraindication | 25702006 | |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Nephritis | contraindication | 52845002 | DOID:10952 |
Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
Psychotic disorder | contraindication | 69322001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Cognitive Impairment following Traumatic Brain Injury | contraindication |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Aldehyde dehydrogenase, mitochondrial | Enzyme | INHIBITOR | WOMBAT-PK | CHEMBL | |||||
Mu-type opioid receptor | GPCR | Ki | 5.85 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.97 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.12 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.74 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 4.16 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 4.66 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.43 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.43 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 6.70 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 5.96 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.61 | DRUG MATRIX | |||||
Cytochrome P450 1A2 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 4.86 | DRUG MATRIX | |||||
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 5.32 | DRUG MATRIX | |||||
C-C chemokine receptor type 5 | GPCR | Ki | 4.74 | DRUG MATRIX | |||||
C-X-C chemokine receptor type 2 | GPCR | Ki | 5.38 | DRUG MATRIX | |||||
C-C chemokine receptor type 2 | GPCR | Ki | 6.02 | DRUG MATRIX | |||||
Mitogen-activated protein kinase 3 | Kinase | IC50 | 5.82 | DRUG MATRIX | |||||
Sodium/nucleoside cotransporter 1 | Transporter | Ki | 5.24 | DRUG MATRIX | |||||
C-C chemokine receptor type 4 | GPCR | Ki | 5.36 | DRUG MATRIX | |||||
Monoglyceride lipase | Enzyme | IC50 | 5.90 | CHEMBL | |||||
Translocator protein | Transporter | WOMBAT-PK | |||||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 4.79 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.67 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 4.33 | DRUG MATRIX | |||||
Aldehyde dehydrogenase, mitochondrial | Enzyme | IC50 | 4.40 | CHEMBL | |||||
Bifunctional protein GlmU | Unclassified | IC50 | 4.07 | CHEMBL |
ID | Source |
---|---|
D004221 | MESH_DESCRIPTOR_UI |
4018494 | VUID |
N0000146816 | NUI |
C0012772 | UMLSCUI |
D00131 | KEGG_DRUG |
2848 | MMSL |
3554 | RXNORM |
387212009 | SNOMEDCT_US |
4623 | MMSL |
d01389 | MMSL |
39516004 | SNOMEDCT_US |
4018494 | VANDF |
000752 | NDDF |
CHEBI:4659 | CHEBI |
CHEMBL964 | ChEMBL_ID |
DB00822 | DRUGBANK_ID |
TR3MLJ1UAI | UNII |
1781 | INN_ID |
7168 | IUPHAR_LIGAND_ID |
3117 | PUBCHEM_CID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0356 | TABLET | 250 mg | ORAL | ANDA | 13 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0357 | TABLET | 500 mg | ORAL | ANDA | 13 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5035 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5036 | TABLET | 500 mg | ORAL | ANDA | 12 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-607 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
Antabuse | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51285-523 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
Antabuse | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51285-524 | TABLET | 500 mg | ORAL | ANDA | 12 sections |
Antabuse | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5034 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-196 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-171 | TABLET | 250 mg | ORAL | ANDA | 12 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-172 | TABLET | 500 mg | ORAL | ANDA | 12 sections |
Disulfiram | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2694 | TABLET | 250 mg | ORAL | ANDA | 12 sections |